Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE - Hata, Akito; Okamoto, Isamu; Inui, Naoki; Okada, Morihito; Morise, Masahiro; Akiyoshi, Kohei; Takeda, Masayuki; Watanabe, Yasutaka; Sugawara, Shunichi; Shinagawa, Naofumi; Kubota, Kaoru; Saeki, Toshiaki; et al. (Journal of clinical oncology, 2022)
Keywords: Adult; Aged; Aged, 80 and over; Antiemetics - adverse effects; Antiemetics - therapeutic use; Antineoplastic Agents - adverse effects; Cisplatin - adverse effects; Dexamethasone - therapeutic use; Double-Blind Method; Drug Combinations; Female; Humans; Isoquinolines - adverse effects; Isoquinolines - therapeutic use; Japan; Male; Middle Aged; Morpholines - adverse effects; Morpholines - therapeutic use; Nausea - chemically induced; Nausea - diagnosis; Nausea - prevention & control; Neurokinin-1 Receptor Antagonists - adverse effects; Neurokinin-1 Receptor Antagonists - therapeutic use; ORIGINAL REPORTS; Pyridines - adverse effects; Pyridines - therapeutic use; Quinuclidines - adverse effects; Quinuclidines - therapeutic use; Time Factors; Treatment Outcome; Vomiting - chemically induced; Vomiting - diagnosis; Vomiting - prevention & control; Japan